NPPA Revises MRPs of 1,085 Anti-Cancer Drugs Under Trade Margin Rationalisation

Exam-focused facts from the 4 November 2026 current affairs briefing.

Key facts

The National Pharmaceutical Pricing Authority (NPPA) updated the revised maximum retail price (MRP) list for 1,085 anti-cancer medicines of different brands, effective November 9.
On October 28, the NPPA revised downward the MRP of 543 anti-cancer medicines, taking the total number of such drugs in the list to 1,085.
The revision follows the NPPA's October 17 announcement enforcing trade margin rationalisation on 137 non-scheduled anti-cancer drugs.
The revised list reflects information submitted by pharmaceutical companies up to November 3 and will be updated as manufacturers submit revised prices.